➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Express Scripts
Moodys
Boehringer Ingelheim
Mallinckrodt

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Litigation Details for In Re Glumetza Antitrust Litigation (N.D. Cal. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

In Re Glumetza Antitrust Litigation (N.D. Cal. 2019)

Docket   Start Trial Date Filed 2019-09-18
Court District Court, N.D. California Date Terminated
Cause 15:1 Antitrust Litigation Assigned To William Haskell Alsup
Jury Demand Both Referred To Robert M. Illman
Parties ALBERTSONS COMPANIES, INC.; ASSERTIO THERAPEUTICS, INC.; BAUSCH HEALTH COMPANIES INC.; BI-LO, LLC; CITY OF PROVIDENCE; CVS PHARMACY, INC.; H-E-B LP; HY-VEE, INC.; KPH HEALTHCARE SERVICES, INC.; KROGER CO., THE; LUPIN LTD.; LUPIN PHARMACEUTICALS, INC.; MEIJER DISTRIBUTION, INC.; MEIJER, INC.; MSP RECOVERY CLAIMS, SERIES LLC; PDL BIOPHARMA, INC.; PENSIONED OPERATING ENGINEERS HEALTH AND WELFARE FUND; RITE AID CORPORATION; RITE AID HDQTRS. CORP.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SERVICE EMPLOYEES INTERNATIONAL UNION LOCAL NO. 1 HEALTH FUND; UFCW LOCAL 1500 WELFARE FUND; WALGREEN CO.; WINN-DIXIE LOGISTICS, INC.
Patents 6,488,962; 6,723,340; 7,780,987; 7,855,223; 8,246,962; 8,258,962; 8,323,692; 8,987,221; 9,855,278; 9,987,263; 9,987,272
Attorneys A.J. De Bartolomeo; Adam Michael Foster; Alberto Rodriguez; Alexander J. Egervary; Andres Rivero; Anna Theresa Neill; Barry L. Refsin; Barry Steven Taus; Brendan Jasper Coffman; Brett H Cebulash; Brian R Morrison; Caitlin V. McHugh; Charles Edward Whorton; Chelsea M. Nichols; Cindy Yuanjia Hong; Daniel Abraham Shmikler; Daniel B. Asimow; David Lee DaPonte; David Paul Germaine; David S. Nalven; Debra G Josephson; Domenico Minerva; Eamon Padraic Kelly; Eric Jonathan Stock; Eric L Bloom; Ethan H. Kaminsky; George G. Gordon; Gregory Asciolla; James Carl Otteson; Jay L. Himes; Jeffrey C. Bank; Jennifer Bridget Patterson; John Paul Bjork; Jorge Alejandro Mestre; Joseph M Vanek; Karen Sharp Halbert; Kristen A. Johnson; Laura S Shores; Lauren C. Ravkind; Lauren G. Barnes; Matthew C. Weiner; Matthew Perez; Michael Roberts; Monica L. Kiley; Nicholas William Shadowen; Nisha Natver Patel; Richard Alan Arnold; Richard M Brunell; Robin van der Meulen; Rochella T. Davis; Sarah E. DeLoach; Saul P. Morgenstern; Scott Eliot Perwin; Service Employees International Union Local No. 1 Health Fund; Shana E. Scarlett; Stephanie Egner Smith; Stephanie Smith; Stephen J. Teti; Steve D. Shadowen; Thomas James Miller; Thomas M. Sobol; Victoria Leigh Weatherford; Wendy Lynn Devine; Whitney E. Street; William Francis Murphy; William Olson
Firms Arnold & Porter Kaye Scholer LLP; Arnold and Porter Kaye Scholer LLP; Baum Hedlund Aristei Goldman, PC; Block & Leviton LLP; Dechert LLP; Dillingham & Murphy; Domenico Minerva; Durie Tangri LLP; George G. Gordon; Gibson, Dunn; Hagens Berman Sobol Shapiro; Hagens Berman Sobol Shapiro LLP; Hangley Aronchick Segal Pudlin & Schiller; Hangley Aronchick Segal Pudlin and Schiller; Hilliard and Shadowen; Hilliard Shadowen, LLP; Kaye Scholer LLP; Kenny Nachwalter, P.A.; Labaton Sucharow LLP; Rivero Mestre; Roberts Law Firm, P.A.; Scott Eliot Perwin; Service Employees International Union Local No. 1 Health Fund; Sperling & Slater, P.C.; Tadler Law LLP; Taus Cebulash & Landau LLP; Taus, Cebulash & Landau, LLP; Vanek Vickers and Masini PC; Vanek Vickers Masini PC; Wilson Sonsini Goodrich & Rosati PC; Wilson Sonsini Goodrich and Rosati, Antitrust
Link to Docket External link to docket
Small Molecule Drugs cited in In Re Glumetza Antitrust Litigation
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in In Re Glumetza Antitrust Litigation

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for In Re Glumetza Antitrust Litigation (N.D. Cal. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-09-18 1 Complaint 6,488,962 (‘962 patent) 6/20/2020 21 6,723,340 (‘340 patent) … 6,488,962 (‘962 patent) 6/20/2020 25 7,780,987 (‘987 patent) …Book patent (the ‘692 patent), as well as two non-Orange Book listed patents 20 (the ‘667 patent and…listed patent(s) and/or the patent is 2 invalid and unenforceable. Simply by listing the patents in the…and U.S. Patent No. 8,329,215 (“the ‘215 patent”)). 21 191. The ‘215 patent, like the ‘667 External link to document
2020-03-05 188 Order on Motion to Dismiss 21 6,340,475; 6,635,280; 6,488,962; and 6,723,340. Lupin had successfully designed around the … 16 for the patent barrier remains. New brand-drug applicants must list the patents (if any) covering…brand drug, that the relevant patents have expired, or that such patents are invalid or will not be … or invalidity against the four relevant patents: U.S. Patent Nos. …infringe the patents 4 because it designed around the patents using a External link to document
2020-04-09 226 Amended Complaint 280 patent) November 6, 2001 October 21, 2003 9/16/2016 13 6,488,962 (’962…Date Expiration Date 18 6,488,962 (’962 patent) June 20, 2000 December…Book patent (the ’692 patent) as well as two non- 28 Orange Book listed patents (the ’667 patent and…Assertio could not patent the drug itself. Instead, Assertio 13 obtained four patents covering extended-release…Lupin would infringe its patents. But Lupin had designed around Assertio’s patents; 6 indeed, before External link to document
2020-08-15 347 Order on Motion to Certify Class 10 6,340,475; 6,635,280; 6,488,962; and 6,723,340. Assertio Therapeutics, Inc. (then owner of … or invalidity against the four relevant patents: U.S. Patent Nos. …analogous anticompetitive behavior, patent misuse, by holding a patent …from an alleged reverse-payment settlement of a patent 17 infringement…restating. This case arises from a perversion of the patent and pharmaceutical- External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKesson
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.